Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 523 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation B Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

NCT05630677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)

NCT07776665
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 1 Interventional Results available

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

NCT03478904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide Liquid, Enzalutamide Capsule
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)

NCT07748351
View directory record Official record
Conditions
Healthy
Interventions
MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), MK-4082 Formulation 4 (F4)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

NCT05236231
View directory record Official record
Conditions
Healthy
Interventions
Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

NCT03305471
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

NCT07361367
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

NCT03137134
View directory record Official record
Conditions
Healthy
Interventions
Crizotinib, Esomeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

NCT04309656
View directory record Official record
Conditions
Multi-drug Resistant Tuberculosis
Interventions
Pretomanid
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

NCT00759902
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Sunitinib in Treating Young Patients With Refractory Solid Tumors

NCT00387920
View directory record Official record
Conditions
Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
15
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

NCT07132983
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

NCT00836953
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Pediatric formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 36 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

NCT01392703
View directory record Official record
Conditions
Pharmacokinetic Study in Healthy Participants
Interventions
Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

NCT05841238
View directory record Official record
Conditions
Healthy, Obese
Interventions
LY3502970
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3074828 in Healthy Participants

NCT03456713
View directory record Official record
Conditions
Healthy
Interventions
LY3074828
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

NCT06477926
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-668 IR, ABBV-668 ER
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710
View directory record Official record
Conditions
Tumor
Interventions
ipilimumab, nivolumab, ENHANZE (rHuPH20)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hartford, Connecticut • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects

NCT05541939
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
Mizagliflozin
Drug
Lead sponsor
Vogenx, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

NCT05137730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Two Salicylic Acid Formulations

NCT00848744
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Formulation A, Formulation B
Drug
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

NCT03828084
View directory record Official record
Conditions
Healthy
Interventions
Decitabine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 20, 2026, 10:04 PM EDT